This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CAMBRIDGE, Mass., Feb. 24, 2011 (GLOBE NEWSWIRE) --
Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 2011 RBC Capital Markets Healthcare Conference in New York City. Marc Beer, CEO of Aegerion, is scheduled to present on a panel titled "New Cardiovascular Drug Therapies" on Wednesday, March 2, 2011, at 2:35 p.m. EST.
A live webcast of the presentation will be available and can be accessed for 90 days following the conference by visiting the "
Investors" section of Aegerion's website,
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.
CONTACT: Aegerion Pharmaceuticals, Inc.
Will Lewis, President
+1 (908) 704-1300
LaVoie Group, Inc.
Investors & Media
+1 (978) 745-4200 x107